BidaskClub lowered shares of Sinovac Biotech, Ltd. (NASDAQ:SVA) from a strong-buy rating to a buy rating in a research report report published on Friday morning.

Separately, ValuEngine raised Sinovac Biotech from a sell rating to a hold rating in a research report on Friday, June 30th.

Shares of Sinovac Biotech (SVA) opened at 6.615 on Friday. The company’s market capitalization is $376.84 million. Sinovac Biotech has a 52-week low of $4.60 and a 52-week high of $6.94. The stock’s 50 day moving average price is $6.42 and its 200 day moving average price is $5.79.

TRADEMARK VIOLATION NOTICE: “Sinovac Biotech, Ltd. (SVA) Lowered to Buy at BidaskClub” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.watchlistnews.com/sinovac-biotech-ltd-sva-lowered-to-buy-at-bidaskclub/1465523.html.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Verity Asset Management Inc. bought a new position in shares of Sinovac Biotech during the first quarter valued at $158,000. Spark Investment Management LLC increased its position in shares of Sinovac Biotech by 62.5% in the first quarter. Spark Investment Management LLC now owns 54,600 shares of the biopharmaceutical company’s stock valued at $312,000 after buying an additional 21,000 shares during the period. Morgan Stanley increased its position in shares of Sinovac Biotech by 86,309.9% in the first quarter. Morgan Stanley now owns 2,721,912 shares of the biopharmaceutical company’s stock valued at $15,597,000 after buying an additional 2,718,762 shares during the period. Eqis Capital Management Inc. increased its position in shares of Sinovac Biotech by 0.6% in the second quarter. Eqis Capital Management Inc. now owns 156,779 shares of the biopharmaceutical company’s stock valued at $1,058,000 after buying an additional 983 shares during the period. Finally, Renaissance Technologies LLC increased its position in shares of Sinovac Biotech by 10.1% in the first quarter. Renaissance Technologies LLC now owns 1,679,490 shares of the biopharmaceutical company’s stock valued at $9,623,000 after buying an additional 154,690 shares during the period. Hedge funds and other institutional investors own 37.93% of the company’s stock.

About Sinovac Biotech

Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps.

Receive News & Ratings for Sinovac Biotech Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinovac Biotech Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.